Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)
Pierre Morel, Christian Buske, Alexander Grunenberg, Efstathios Kastritis, Lydia Montes, Cécile Tomowiak, Roman Hájek, Andreas Viardot, Olivier Tournilhac, Thérèse Aurran, Florian Bouclet, Hacène Zerazhi, Bénédicte Hivert, Damien Roos‐Weil, Sophie de Guibert, Lena Brandefors, Ramón García‐Sánz, Maria Fátima das Graças Fernandes da Silva, Eva Kimby, Birgit Schmelzle, Dajana Kaszynski, Mélanie Verlay, Caroline Skrzypczak, Jens Dreyhaupt, Rainer Muche, Meletios A Dimopoulos (2025). Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM). , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-223.
Article39 days agoDetermining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia
Philipp Nakov, Daniela Drandi, Lisa Kaiser, Dajana Kaszynski, Alexander Grunenberg, Jasmin Mark, E Runge, Meletios A Dimopoulos, Efstathios Kastritis, Tina Bagratuni, Christian Buske, Christiane Pott, Simone Ferrero, Mouhamad Khouja (2024). Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-204645.
Article39 days agoBortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>
Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot, Dajana Kaczynski, Heike Mund, Katja Gutmair, Matthias Zingerle, Paul Duewel, Susanne Saußele, Björn Schöttker, Ullrich Graeven, Martin Dreyling, Andrea Kerkhoff, Thomas Weber, Holger Hebart, Ralf Ulrich Trappe, Lisa Kaiser, E Runge, Jasmin Mark, Simone Ferrero, Daniela Drandi, Falko Fend, Irina Bonzheim, Eva Hoster, Jens Dreyhaupt, Meletios A Dimopoulos (2024). Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200604.
Article38 days agoBortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
Christian Buske, Meletios A Dimopoulos, Alexander Grunenberg, Efstathios Kastritis, Cécile Tomowiak, Beatrice Mahé, Xavier Troussard, Roman Hájek, Andreas Viardot, Olivier Tournilhac, Thérèse Aurran, Stéphane Leprêtre, Hacène Zerazhi, Bénédicte Hivert, Véronique Leblond, Sophie de Guibert, Lena Brandefors, Ramón García‐Sánz, María Gomes da Silva, Eva Kimby, Birgit Schmelzle, Dajana Kaszynski, Jens Dreyhaupt, Rainer Muche, Pierre Morel (2023). Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. , 41(14), DOI: https://doi.org/10.1200/jco.22.01805.
Article38 days agoBortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>
Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot, Dajana Kaczynski, Heike Mund, Katja Gutmair, Matthias Zingerle, Paul Duewel, Susanne Saußele, Björn Schöttker, Ullrich Graeven, Martin Dreyling, Andrea Kerkhoff, Thomas Weber, Holger Hebart, Ralf Ulrich Trappe, Lisa Kaiser, E Runge, Jasmin Mark, Simone Ferrero, Daniela Drandi, Falko Fend, Irina Bonzheim, Eva Hoster, Jens Dreyhaupt, Meletios A Dimopoulos (2024). Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200604.
Article38 days ago